You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 552 SUMOylation inhibitor TAK-981 activates NK cells and macrophages via Type I interferon signaling and shows synergistic activity in combination with rituximab and daratumumab in preclinical models

Article Text

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Immune-stimulants and immune modulators
552 SUMOylation inhibitor TAK-981 activates NK cells and macrophages via Type I interferon signaling and shows synergistic activity in combination with rituximab and daratumumab in preclinical models

https://doi.org/10.1136/jitc-2020-SITC2020.0552

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.